How Purdue’s ‘one-two’ punch fuelled the opioids market

Accused of exaggerating the benefits of OxyContin, the company’s owners had a bigger share than realised
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news